Clik here to view.
Modalis Therapeutics has received an Orphan Drug Designation from the U.S....
TOKYO & WALTHAM, Mass. Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883, CEO: Haru Morita), a leading company pioneering treatments for rare genetic diseases using its proprietary...
View ArticleClik here to view.
Clik here to view.
JCR Pharmaceuticals Presents Preclinical Gene Therapy Research at the...
HYOGO, Japan JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that the Company presented preclinical data from its novel adeno-associated virus...
View ArticleClik here to view.
Fujita Health University and BostonGene Expand Access to Genomic Cancer...
TOKYO & WALTHAM, Mass. Fujita Health University and BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced today that the Fujita Health University Haneda...
View ArticleClik here to view.
藤田医科大学羽田クリニックにおいてBostonGene 社が開発したTumor Portrait™検査を導入。がん患者さんの包括的ゲノム検査として開始します。
東京 & WALTHAM, Mass. （ビジネスワイヤ） — AIによる分子免疫プロファイリングソリューションのリーディングカンパニーであるBostonGeneは、藤田医科大学羽田クリニックにてBostonGene社開発の Tumor Portrait™を用いたがんゲノムプロファイリング検査を開始します。...
View ArticleClik here to view.
JCR Pharmaceuticals to Present at the European Society of Gene and Cell...
HYOGO, Japan JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that it will present preclinical data from its proprietary J-Brain Cargo®-applied...
View ArticleClik here to view.
MEDiC Life Sciences Announces Collaboration with Hanmi Pharmaceutical on...
MOUNTAIN VIEW, Calif. MEDiC Life Sciences (“MEDiC”), a Silicon Valley biotech startup, today announced that it has entered a research collaboration with Hanmi Pharmaceutical (“Hanmi”), a leading...
View ArticleClik here to view.
Inocras Unveils Breakthrough Study, Proving Target-Enhanced Whole-Genome...
SAN DIEGO Inocras, an industry leader in whole genome sequencing and bioinformatics, released a new study highlighting the clinical validation of its CancerVision Target-Enhanced Whole-Genome...
View ArticleClik here to view.
Lifebit and Flatiron Health Bring Cutting-Edge Research Technology to Japan,...
TOKYO Flatiron Health, and Lifebit Biotech Ltd (UK, London; hereafter “Lifebit”), are expanding their collaboration into Japan to transform cancer care, facilitating ground breaking research by...
View ArticleClik here to view.
Ferring Pharmaceuticals bolsters global gene therapy supply chain with...
SAINT-PREX, Switzerland Ferring Pharmaceuticals today announced the opening of a state-of-the-art global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene...
View ArticleClik here to view.
Global Healthy Living Foundation Partners with The Bone Bus to Enhance Rural...
UPPER NYACK, N.Y. & SYDNEY The Global Healthy Living Foundation Australia (GHLF Australia) is proud to announce its collaboration with The Bone Bus, an Australian traveling bone density...
View ArticleClik here to view.
PHC、独自のIn-Lineモニタリング技術を活用した自動培養装置「LiCellGrow」のプロトタイプを「再生医療JAPAN 2024」に出展
東京 （ビジネスワイヤ） — PHC株式会社 バイオメディカ事業部（本社：東京都千代田区、代表取締役社長：中村 伸朗、以下「バイオメディカ事業部」）は、10月9日（水）から10月11日（金）までパシフィコ横浜で開催される「再生医療JAPAN...
View ArticleClik here to view.
KalVista Announces the Submission of Additional Marketing Authorization...
CAMBRIDGE, Mass. & SALISBURY, England KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced Marketing Authorization Application (MAA) submissions to the regulatory authorities in the...
View ArticleClik here to view.
Modalis Therapeutics: FDA Grants Rare Pediatric Disease Designation to...
TOKYO & WALTHAM, Mass. Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883, CEO: Haru Morita), a leading company pioneering treatments for rare genetic diseases using its proprietary...
View ArticleClik here to view.
SKファームテコ、小分子およびペプチドのグローバル生産を拡大すべく2億6,000万ドルを投資
カリフォルニア州ランチョコルドバ （ビジネスワイヤ） — 世界的な医薬品開発・製造受託機関（CDMO）であるSKファームテコは、2億6,000万ドルの投資を通じて韓国の世宗（セジョン）に最新鋭の施設を新設し、小分子およびペプチドの生産能力を大幅に拡大すると発表しました。...
View ArticleClik here to view.
SK pharmteco Invests $260 Million to Expand Global Small Molecule and Peptide...
RANCHO CORDOVA, Calif. SK pharmteco, a global contract development and manufacturing organization (CDMO), today announced a major expansion of its small molecule and peptide production capabilities...
View ArticleClik here to view.
Promega Engineers New Enzyme to Significantly Reduce Stutter in Forensic DNA...
MADISON, Wis. A novel enzyme developed by research scientists at Promega Corporation will virtually eliminate confounding stutter artifacts in forensic DNA analysis. The reduced stutter polymerase...
View ArticleClik here to view.
Aurion Biotech Launches Vyznova® (neltependocel) in Japan for the Treatment...
SEATTLE & CAMBRIDGE, Mass. & TOKYO Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced the commercial launch...
View ArticleClik here to view.
Aurion Biotech在日本推出用于治疗大疱性角膜病变的Vyznova® (neltependocel)
西雅图、马萨诸塞州剑桥和东京 (美国商业资讯)– Aurion Biotech的使命是通过改变人生的再生疗法恢复数百万患者的视力，公司今天宣布开始在日本市售用于治疗大疱性角膜病变的Vyznova®（通用名称：neltependocel）。公司相信，这是第一种获批用于治疗角膜内皮疾病的细胞疗法；它已在日本获得监管和报销批准。伴随此次商业发布，日本京都府立医科大学(KPUM)的Shigeru...
View ArticleClik here to view.
PHC、細胞の代謝変化をリアルタイムに可視化するライブセル代謝分析装置「LiCellMoTM（リセルモ）」を発売
東京 （ビジネスワイヤ） — PHC株式会社 バイオメディカ事業部（本社：東京都千代田区、代表取締役社長：中村...
View Article
